Cannabinoid Signaling in Cancer

Das, Subhadip; Kaul, Kirti; Mishra, Sanjay; Charan, Manish; Ganju, Ramesh K.

doi:10.1007/978-3-030-21737-2_4

Cited by 20 publications

(21 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to CBD, which has been reported to have a good safety profile [15], THC has been reported to induce dose-dependent performance impairment, as well as to increase anxiety, psychotic symptoms, heart rate, blood pressure, and to alter perception. By mixing CBD with THC, the side effects of THC were reduced, since CBD is a negative allosteric modulator of CB1, the major cannabinoid-selective receptor in the brain [53], and also antagonizes THC-mediated undesired downregulation of its anti-tumour immunity [46,47] which should be avoided [14,15]. Strategically combining the two agents in targeting GB cells by different mechanisms leading to the similar end points in tumour elimination and in general, such strategy improves the therapeutic index of certain drugs while reducing undesired side effects [24].…”

Section: Discussionmentioning

confidence: 99%

“…Based on multiple effects of CBD, CBG, and THC in differentiated GB and GB stem cells, we wanted to gain information on whether the major two cannabinoids receptors, CB1 and CB2 are expressed in the established and primary GSC cell lines, as their expression in GB has been confirmed in the literature [33,[46][47][48]. We found that both CB1 and CB2 receptors were highly, but differentially, expressed in primary GB cells, indicating large patient variability in this respect (Figure 8A,B).…”

Section: The Cannabinoid Receptors Cb1 and Cb2 Are Highly But Differementioning

confidence: 99%

See 1 more Smart Citation

Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma

Lah

Novak

Almidon

et al. 2021

Cells

View full text Add to dashboard Cite

Glioblastoma is the most aggressive cancer among primary brain tumours. As with other cancers, the incidence of glioblastoma is increasing; despite modern therapies, the overall mean survival of patients post-diagnosis averages around 16 months, a figure that has not changed in many years. Cannabigerol (CBG) has only recently been reported to prevent the progression of certain carcinomas and has not yet been studied in glioblastoma. Here, we have compared the cytotoxic, apoptotic, and anti-invasive effects of the purified natural cannabinoid CBG together with CBD and THC on established differentiated glioblastoma tumour cells and glioblastoma stem cells. CBG and THC reduced the viability of both types of cells to a similar extent, whereas combining CBD with CBG was more efficient than with THC. CBD and CBG, both alone and in combination, induced caspase-dependent cell apoptosis, and there was no additive THC effect. Of note, CBG inhibited glioblastoma invasion in a similar manner to CBD and the chemotherapeutic temozolomide. We have demonstrated that THC has little added value in combined-cannabinoid glioblastoma treatment, suggesting that this psychotropic cannabinoid should be replaced with CBG in future clinical studies of glioblastoma therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: The Cannabinoid Receptors Cb1 and Cb2 Are Highly But Differementioning

confidence: 99%

Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma

Lah

Novak

Almidon

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…Cannabinoid signaling regulates several pathways in cancer and immune cells [ 83 ]. Cannabinoids reduce tumor proliferation by inhibiting the activation of the AKT [ 15 , 84 ], EGFR, ERK, and nuclear factor kappa beta (NF-κβ) signaling pathways [ 84 , 85 ].…”

Section: Discussionmentioning

confidence: 99%

“…In addition, these compounds were evaluated in cultures mimicking the environment found in vivo and have shown promise in counteracting the synergistic crosstalk that occurs between cancer cells and the tumor microenvironment (TME) [ 91 , 92 , 93 , 94 ]. The modulation of the TME is important, since the TME plays a vital role in tumor development, invasion, and metastasis [ 83 ].…”

Section: Discussionmentioning

confidence: 99%

Cannabinoid Combination Induces Cytoplasmic Vacuolation in MCF-7 Breast Cancer Cells

2020

View full text Add to dashboard Cite

This study evaluated the synergistic anti-cancer potential of cannabinoid combinations across the MDA-MB-231 and MCF-7 human breast cancer cell lines. Cannabinoids were combined and their synergistic interactions were evaluated using median effect analysis. The most promising cannabinoid combination (C6) consisted of tetrahydrocannabinol, cannabigerol (CBG), cannabinol (CBN), and cannabidiol (CBD), and displayed favorable dose reduction indices and limited cytotoxicity against the non-cancerous breast cell line, MCF-10A. C6 exerted its effects in the MCF-7 cell line by inducing cell cycle arrest in the G2 phase, followed by the induction of apoptosis. Morphological observations indicated the induction of cytoplasmic vacuolation, with further investigation suggesting that the vacuole membrane was derived from the endoplasmic reticulum. In addition, lipid accumulation, increased lysosome size, and significant increases in the endoplasmic reticulum chaperone protein glucose-regulated protein 78 (GRP78) expression were also observed. The selectivity and ability of cannabinoids to halt cancer cell proliferation via pathways resembling apoptosis, autophagy, and paraptosis shows promise for cannabinoid use in standardized breast cancer treatment.

show abstract

“…Lastly, cannabinoids could be also useful to control the toxicity of protein aggregates (e.g. mSOD1, TDP‐43 and FUS) in ALS, as cannabinoids have been found to enhance autophagy by inhibiting mTOR signalling (Das et al, 2019). However, this possibility still needs to be investigated in experimental models of ALS (see below).…”

Section: Cannabinoids and Alsmentioning

confidence: 99%

Targeting the CB₂ receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

Rodríguez‐Cueto

García-Toscano

Santos‐García

et al. 2021

British J Pharmacology

View full text Add to dashboard Cite

Cannabinoids form a singular group of plant‐derived compounds, endogenous lipids and synthetic derivatives with multiple therapeutic effects exerted by targeting different elements of the endocannabinoid system. One of their therapeutic applications is the preservation of neuronal integrity exerted by attenuating the multiple neurotoxic events that kill neurons in neurodegenerative disorders. In this review, we will address the potential of cannabinoids as neuroprotective agents in amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disorder characterized by muscle denervation, atrophy and paralysis, and progressive deterioration in upper and/or lower motor neurons. The emphasis will be paid on the cannabinoid type 2 (CB2) receptor, whose activation limits glial reactivity, but the potential of additional endocannabinoid‐related targets will be also addressed. The evidence accumulated so far at the preclinical level supports the need to soon move towards the patients and initiate clinical trials to confirm the potential of cannabinoid‐based medicines as disease modifiers in ALS. LINKED ARTICLES This article is part of a themed issue on Neurochemistry in Japan. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.6/issuetoc

show abstract

Cannabinoid Signaling in Cancer

Cited by 20 publications

References 80 publications

Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma

Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma

Cannabinoid Combination Induces Cytoplasmic Vacuolation in MCF-7 Breast Cancer Cells

Targeting the CB₂ receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

Contact Info

Product

Resources

About

Cannabinoid Signaling in Cancer

Cited by 20 publications

References 80 publications

Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma

Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma

Cannabinoid Combination Induces Cytoplasmic Vacuolation in MCF-7 Breast Cancer Cells

Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

Contact Info

Product

Resources

About

Targeting the CB₂ receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis